Manuel Schmidt

1.3k total citations
50 papers, 1.0k citations indexed

About

Manuel Schmidt is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Manuel Schmidt has authored 50 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 29 papers in Immunology and 13 papers in Molecular Biology. Recurrent topics in Manuel Schmidt's work include Immunotherapy and Immune Responses (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Immune Cell Function and Interaction (11 papers). Manuel Schmidt is often cited by papers focused on Immunotherapy and Immune Responses (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Immune Cell Function and Interaction (11 papers). Manuel Schmidt collaborates with scholars based in Germany, United States and Spain. Manuel Schmidt's co-authors include Burghardt Wittig, Andreas Neubauer, Albert Descoteaux, Jutta Proba, Markus Ritter, Werner Scheithauer, Stefan Nagel, Hans‐Joachim Schmoll, Jeffrey F. Waring and Frank Rosenbauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Manuel Schmidt

48 papers receiving 970 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manuel Schmidt Germany 14 603 353 273 214 145 50 1.0k
Claude Baillou France 20 467 0.8× 243 0.7× 449 1.6× 442 2.1× 214 1.5× 56 1.3k
J. Joseph Melenhorst United States 18 624 1.0× 348 1.0× 249 0.9× 275 1.3× 77 0.5× 32 1.0k
Suzanne Skoda‐Smith United States 13 579 1.0× 137 0.4× 394 1.4× 172 0.8× 78 0.5× 26 1.0k
D T Fearon United States 16 1.3k 2.2× 192 0.5× 359 1.3× 286 1.3× 139 1.0× 17 1.7k
Sambasiva P. Rao United States 12 803 1.3× 122 0.3× 195 0.7× 78 0.4× 73 0.5× 21 1.1k
Laura Pattacini Italy 13 247 0.4× 87 0.2× 159 0.6× 196 0.9× 132 0.9× 26 624
Naotaka Shibagaki Japan 16 372 0.6× 278 0.8× 362 1.3× 48 0.2× 44 0.3× 42 920
Ido Lubin Israel 19 481 0.8× 140 0.4× 220 0.8× 312 1.5× 100 0.7× 43 1.1k
MA Caligiuri United States 9 671 1.1× 229 0.6× 217 0.8× 329 1.5× 138 1.0× 10 1.1k
Jantine E. Bakema Netherlands 19 827 1.4× 196 0.6× 310 1.1× 69 0.3× 63 0.4× 28 1.2k

Countries citing papers authored by Manuel Schmidt

Since Specialization
Citations

This map shows the geographic impact of Manuel Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Schmidt more than expected).

Fields of papers citing papers by Manuel Schmidt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Schmidt. The network helps show where Manuel Schmidt may publish in the future.

Co-authorship network of co-authors of Manuel Schmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Schmidt. A scholar is included among the top collaborators of Manuel Schmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Schmidt. Manuel Schmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Curran, Michael A., et al.. (2019). EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 7(1). 5–5. 8 indexed citations
2.
Schmidt, Manuel, et al.. (2018). A new family of potent TLR9 agonists, EnanDIM, which inhibit tumor growth in various syngeneic murine models. European Journal of Cancer. 92. S5–S6. 1 indexed citations
3.
Cunningham, David, Eric Van Cutsem, Ramón Salazar, et al.. (2017). Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma. Annals of Oncology. 28. xi27–xi27. 2 indexed citations
4.
Wittig, Burghardt, et al.. (2017). Abstract 2622: Two new TLR9 agonists for cancer immunotherapy: Combination with checkpoint inhibitors. Cancer Research. 77(13_Supplement). 2622–2622. 1 indexed citations
5.
Thomas, Michael, Santiago Ponce-Aix, Alejandro Navarro, et al.. (2017). Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod. Annals of Oncology. 28. v539–v539. 5 indexed citations
6.
Schmidt, Manuel, et al.. (2017). The TLR9 agonist lefitolimod modulates tumor microenvironment and improves anti-tumor effect of checkpoint inhibitors in vivo. Annals of Oncology. 28. v577–v578. 1 indexed citations
7.
Schmidt, Manuel, et al.. (2016). Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist. Molecular Therapy — Oncolytics. 3. 15023–15023. 5 indexed citations
8.
Schmidt, Manuel, et al.. (2015). Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703. Nucleic Acid Therapeutics. 25(3). 130–140. 38 indexed citations
9.
Schmidt, Manuel, et al.. (2015). ITOC2 – 035. The immunotherapeutic TLR-9 agonist MGN1703 – Pharmacokinetic and pharmacodynamic data from healthy volunteers and cancer patients. European Journal of Cancer. 51. S12–S12. 2 indexed citations
10.
Kobelt, Dennis, Jutta Aumann, Manuel Schmidt, et al.. (2014). Preclinical study on combined chemo‐ and nonviral gene therapy for sensitization of melanoma using a human TNF‐alpha expressing MIDGE DNA vector. Molecular Oncology. 8(3). 609–619. 11 indexed citations
11.
Grünwald, Viktor, S. Weikert, I G Schmidt-Wolf, et al.. (2014). Aset Study: Final Results of Patients with Locally Recurrent or Metastatic Renal Cell Carcinoma (Rcc) Treated with Mgn1601. Annals of Oncology. 25. iv366–iv366. 2 indexed citations
12.
Grünwald, Viktor, Steffen Weikert, Stefan Hauser, et al.. (2012). New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 30(5_suppl). 398–398.
13.
Weikert, Steffen, Viktor Grünwald, Stefan Hauser, et al.. (2012). Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology. 30(15_suppl). 4636–4636. 1 indexed citations
14.
Kobelt, Dennis, Jutta Aumann, Manuel Schmidt, et al.. (2012). Intratumoral Dispersion, Retention, Systemic Biodistribution, and Clearance of a Small-Size Tumor Necrosis Factor-α-Expressing MIDGE Vector After Nonviral in Vivo Jet-Injection Gene Transfer. Human Gene Therapy Methods. 23(4). 264–270. 5 indexed citations
15.
16.
Köchling, Joachim, Javier Prada, Renata Stripecke, et al.. (2008). Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine. 26(36). 4669–4675. 19 indexed citations
17.
Chung, June‐Key, et al.. (2007). MIDGE/hNIS vaccination generates antigen‐associated CD8+IFN‐γ+ T cells and enhances protective antitumor immunity. International Journal of Cancer. 120(9). 1942–1950. 11 indexed citations
18.
19.
20.
Schmidt, Manuel, Stefan Nagel, Jutta Proba, et al.. (1998). Lack of Interferon Consensus Sequence Binding Protein (ICSBP) Transcripts in Human Myeloid Leukemias. Blood. 91(1). 22–29. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claude Baillou Breakdown of academic impact, for papers by J. Joseph Melenhorst Breakdown of academic impact, for papers by Suzanne Skoda‐Smith Breakdown of academic impact, for papers by D T Fearon Breakdown of academic impact, for papers by Sambasiva P. Rao Breakdown of academic impact, for papers by Laura Pattacini Breakdown of academic impact, for papers by Naotaka Shibagaki Breakdown of academic impact, for papers by Ido Lubin Breakdown of academic impact, for papers by MA Caligiuri Breakdown of academic impact, for papers by Jantine E. Bakema
Rankless by CCL
2026